Mariner’s Puma Biotechnology PBYI Stock Holding History

Mariner’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$121K	Buy	14,869 +220	+2%	+$1.61K	﹤0.01%	3297
2026 Q1	$93.6K	Buy	+14,649	New	+$94.5K	﹤0.01%	3336

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mariner's PBYI Position: Q2 2026 in Review

Mariner increased its Puma Biotechnology (PBYI) stake by 1.5% in Q2 2026, buying an estimated $1.61K and bringing the position to 14,869 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #3297.

Mariner first reported a position in PBYI in Q1 2026 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

Mariner held 14,869 shares of Puma Biotechnology worth $121K as of Q2 2026.
Mariner bought 220 Puma Biotechnology shares in Q2 2026, an estimated $1.61K.
Puma Biotechnology made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3297 holding.
Mariner first reported a position in Puma Biotechnology in Q1 2026 and has held it in 2 quarters since.
161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.